IMU Biosciences Raises $53M to Advance AI-Driven Immune System Profiling Platform
核心洞察
IMU Biosciences (搜索) completed an oversubscribed Series A extension totaling over $53 million, co-led by IQ Capital (搜索) and Molten Ventures (搜索) with participation from British Business Bank (搜索) and existing investors.
The London-based company has built the world's largest immune dataset with over 25,000 individuals and 100 million immune data points from single blood samples using its CytAtlas platform.
The funding will support clinical programs in stem cell transplantation, solid organ transplantation, and immuno-oncology, aiming to establish universal standards for immune profiling in precision medicine.
IMU Biosciences (搜索) has secured over $53 million in an oversubscribed Series A extension to advance its artificial intelligence-driven immune system (搜索) profiling platform. The London-based biotechnology company announced the funding round was co-led by IQ Capital (搜索) and Molten Ventures (搜索), with participation from the British Business Bank (搜索), Meltwind, and existing investors.
The company has developed what it describes as the world's largest immune dataset, encompassing samples from more than 25,000 individuals and generating over 100 million immune data points from a single blood sample. IMU's CytAtlas platform combines advanced multi-omic profiling with machine learning to create high-definition maps of the immune system (搜索), capable of resolving approximately 2,500 immune cell subsets in real-time from just 2ml of blood.
Clinical Applications and Development Programs
The new capital will support operational expansion and advancement of clinical programs across three key therapeutic areas where immune status plays a decisive role. In hematopoietic stem cell transplantation, IMU is developing predictive tools for graft efficacy. For solid organ transplantation, the company is working on tools to predict graft rejection. In immuno-oncology, researchers are identifying immune signatures that could predict response and adverse events to checkpoint inhibitors (搜索).
The funding also supports IMU's participation in MANIFEST, a major UK research consortium investigating patient responses to cancer (搜索) immunotherapies. Led by the Francis Crick Institute (搜索), this project studies tumor and blood samples from 3,000 cancer patients to identify biomarkers linked to treatment response, relapse, and disease detection.
Scientific Foundation and Leadership
IMU Biosciences (搜索) was founded in 2021 by Dr. Adam Laing, Dr. Tom Hayday, and Mario Cantero, building on ten years of research from King's College London and The Francis Crick Institute (搜索). Dr. John Baker joined as CEO in September 2024, bringing executive experience from Abcam (搜索) during its $5.7 billion acquisition by Danaher (搜索).
The founding team identified a fundamental limitation in current immune system (搜索) analysis, where existing tools often provide fragmented snapshots rather than complete pictures of immune behavior. This makes it difficult to understand disease progression, treatment response, or patient-specific immune characteristics.
Investor Perspectives and Market Position
Dr. Inga Deakin, Partner at Molten Ventures (搜索) and IMU's largest shareholder, stated: "When we first invested in IMU in 2024, we believed deep immune profiling combined with AI could transform precision medicine. Since then, the team has consistently delivered. The immune system (搜索) sits at the heart of almost every disease, and IMU's ability to analyse it at this resolution could redefine how treatments are matched to patients."
Dr. Alex Wilson, Partner at IQ Capital (搜索), noted: "With the world's largest immune dataset and proprietary machine learning analytics, the company is unlocking the value of health data to deliver better insights for clinicians and improved outcomes for patients."
The company operates in a competitive landscape that includes Isomorphic Labs, which raised $2.1 billion in Series B funding, and Owkin, which has raised $334 million total. However, IMU differentiates itself through exclusive focus on immune intelligence rather than broader drug discovery applications.
Platform Technology and Clinical Translation
IMU's approach aims to establish a universal standard for immune profiling that could underpin diagnosis, patient stratification, treatment monitoring, and therapeutic development across multiple disease areas simultaneously. The platform combines scale, standardization, and computational analysis to move beyond fragmented snapshots of immune activity toward actionable pictures of immune health and disease.
While immune profiling has long been central to research, its translation into routine clinical decision-making remains technically demanding. IMU's strategy focuses on building foundational immune profiling standards that could change not only how diseases are treated, but how they are understood fundamentally.
The latest funding follows IMU's earlier rounds, including an $11.5 million investment announced in 2024. The company is positioning itself at the intersection of biotechnology, machine learning, and personalized medicine as healthcare moves toward precision treatments tailored to individual patients rather than broad populations.